Mitochondria-Targeting Antimicrobial Peptide (AMP) Regulating N6-Methyladenosine (m6A) Modification to Promote Colon Cancer Ferroptosis
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Chenyu Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China. Hauptthemen laut MEDLINE: Adenosine, Colonic Neoplasms, Mitochondria, Ferroptosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Colon cancer (COAD) is one of the common malignant tumors in the gastrointestinal tract; it is urgent to deeply study the mechanism of COAD and develop new therapeutic agents, which will provide new hope for improving the therapeutic efficacy and prolonging the survival of patients. Mitochondria are crucial organelles that play an important role in COAD, participating in cellular energy and material metabolism and playing a key role in the regulation of cell death, making mitochondria a potential target for COAD therapy. In this study, we designed an antimicrobial peptide (AMP) that can target tumor cells and act on mitochondria. The AMP is taken up by tumor cells and can achieve colocalization with mitochondria, reducing the mitochondrial membrane potential levels in tumor cells and inducing ferroptosis. The AMP affects N6-methyladenosine (m6A) methylation modification in cells and participates in the regulation of ferroptosis. During in vivo experiments on COAD, the AMP demonstrated a strong ability to inhibit tumor growth and good biosafety. Unlike peptide–drug conjugates that rely on toxin release, the synthetic AMP exerts direct targeted activity with improved biosafety and efficiency. The AMP effectively suppresses the development of COAD, providing a new reference method for the treatment of COAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
- College of Pharmacy, Dalian Medical University, Dalian 116044, China.
- The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110847, China.
- Department of Cardiology, Institute of Cardiovascular Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
ORCID-Profile: Shuai Li
Zitieren
APA
Li, C., Li, S., Lv, L., Chen, Y., Yang, S., Lu, Y., & Dong, D. (2025). Mitochondria-Targeting Antimicrobial Peptide (AMP) Regulating N6-Methyladenosine (m6A) Modification to Promote Colon Cancer Ferroptosis. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00459
Vancouver
Li C, Li S, Lv L, Chen Y, Yang S, Lu Y, et al. Mitochondria-Targeting Antimicrobial Peptide (AMP) Regulating N6-Methyladenosine (m6A) Modification to Promote Colon Cancer Ferroptosis. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00459
BibTeX
@article{Li2025,
author = {Li, Chenyu and Li, Shuai and Lv, Linlin and Chen, Yanwei and Yang, Shilei and Lu, Yan and Dong, Deshi},
title = {Mitochondria-Targeting Antimicrobial Peptide (AMP) Regulating N6-Methyladenosine (m6A) Modification to Promote Colon Cancer Ferroptosis},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00459}
}
EUVIMED